| Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation AM Gianni, M Bregni, AC Stern, S Siena, C Tarella, A Pileri, G Bonadonna The Lancet 334 (8663), 580-585, 1989 | 960 | 1989 |
| High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma AM Gianni, M Bregni, S Siena, C Brambilla, M Di Nicola, F Lombardi, ... New England Journal of Medicine 336 (18), 1290-1298, 1997 | 646 | 1997 |
| Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi … A Gallamini, F Zaja, C Patti, A Billio, MR Specchia, A Tucci, A Levis, ... Blood, The Journal of the American Society of Hematology 110 (7), 2316-2323, 2007 | 392 | 2007 |
| Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic … P Corradini, A Dodero, F Zallio, D Caracciolo, M Casini, M Bregni, F Narni, ... Journal of Clinical Oncology 22 (11), 2172-2176, 2004 | 376 | 2004 |
| Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells P Corradini, C Voena, C Tarella, M Astolfi, M Ladetto, A Palumbo, ... Journal of Clinical Oncology 17 (1), 208-208, 1999 | 309 | 1999 |
| Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation P Corradini, C Tarella, F Zallio, A Dodero, M Zanni, P Valagussa, ... Leukemia 20 (9), 1533-1538, 2006 | 308 | 2006 |
| Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion M Magni, M Di Nicola, L Devizzi, P Matteucci, F Lombardi, L Gandola, ... Blood, The Journal of the American Society of Hematology 96 (3), 864-869, 2000 | 306 | 2000 |
| Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis … M Ladetto, F De Marco, F Benedetti, U Vitolo, C Patti, A Rambaldi, ... Blood, The Journal of the American Society of Hematology 111 (8), 4004-4013, 2008 | 293 | 2008 |
| Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) AM Gianni, M Magni, M Martelli, M Di Nicola, C Carlo-Stella, S Pilotti, ... Blood 102 (2), 749-755, 2003 | 289 | 2003 |
| Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease S Gaia, A Smedile, P Omedè, A Olivero, F Sanavio, F Balzola, A Ottobrelli, ... Journal of hepatology 45 (1), 13-19, 2006 | 235 | 2006 |
| Ras oncogene mutation in multiple myeloma. A Neri, JP Murphy, L Cro, D Ferrero, C Tarella, L Baldini, R Dalla-Favera The Journal of experimental medicine 170 (5), 1715-1725, 1989 | 232 | 1989 |
| Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients A Palumbo, S Triolo, C Argentino, S Bringhen, A Dominietto, C Rus, ... Blood, The Journal of the American Society of Hematology 94 (4), 1248-1253, 1999 | 227 | 1999 |
| Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B G Todeschini, S Secchi, E Morra, U Vitolo, E Orlandi, F Pasini, E Gallo, ... British journal of cancer 90 (2), 372-376, 2004 | 222 | 2004 |
| Proposed definition of ‘poor mobilizer’in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo A Olivieri, M Marchetti, R Lemoli, C Tarella, A Iacone, F Lanza, ... Bone marrow transplantation 47 (3), 342-351, 2012 | 219 | 2012 |
| Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell … P Corradini, M Astolfi, C Cherasco, M Ladetto, C Voena, D Caracciolo, ... Blood, The Journal of the American Society of Hematology 89 (2), 724-491, 1997 | 214 | 1997 |
| Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP … RU Trappe, D Dierickx, H Zimmermann, F Morschhauser, P Mollee, ... Journal of Clinical Oncology 35 (5), 536-543, 2017 | 196 | 2017 |
| Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed … A Gallamini, C Tarella, S Viviani, A Rossi, C Patti, A Mulé, M Picardi, ... Journal of Clinical Oncology 36 (5), 454-462, 2018 | 190 | 2018 |
| Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies P Corradini, C Tarella, A Olivieri, AM Gianni, C Voena, F Zallio, M Ladetto, ... Blood, The Journal of the American Society of Hematology 99 (1), 75-82, 2002 | 187 | 2002 |
| High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting P Corradini, C Voena, M Astolfi, M Ladetto, C Tarella, M Boccadoro, ... Blood 85 (6), 1596-1602, 1995 | 181 | 1995 |
| Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in … C Tarella, R Passera, M Magni, F Benedetti, A Rossi, A Gueli, C Patti, ... Journal of Clinical Oncology 29 (7), 814-824, 2011 | 176 | 2011 |
